We are now officially introduce Pharma Sources Insight (June 2020) for the global readers to get access to the new developments on the COVID-19 treatments, new drug approvals, sales ranking list of a specific category of drugs and potential R&D areas, focusing on the Chinese pharmaceutical industry, and with a global vision.
Pharma Sources Insight is a selection of hot articles on PharmaSources.com, with the contribution from the PharmaSources.com expert writers who are not only active leaders and independent writers in their own expertise, such as health and biotech, FDA review and approval, serialization and digitalization, etc. but also good at capturing the market trends and willing to share their views.
As a vertical B2B website serving the pharmaceutical industry operated by CPhI & P-MEC China of Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd., PharmaSources.com has been re-launched in April as an updated edition of En-CPhI.CN.
With the promotion of the “Pharma Sources Insight” E-compilation, PharmaSources.com is dedicated to serving and connecting the suppliers and buyers, helping pharmaceutical professionals to better understand the Chinese markets until reaching deals. In the meantime, PharmaSources.com will spare no effort to incorporate quality original content, and to continuously share popular pharma articles on the platform, together to witness the current events and future evolutions in the pharmaceutical field.
Pharma Sources Insight June 2020 focuses on the following topics:
-A Post-pandemic Future
-How will the Epidemic’s Identification as a PHEIC Affect China’s API Export?
-A Review of the Three Chinese Patent Medicines Affirmed by the National Administration of TCM of China to Treat COVID-19
-A Quick Look at the Anti-epidemic Monoclonal Antibodies that Target the Novel Coronavirus S Protein
-Cell and Gene Therapies: Keep Calm and Carry On
-FDA Fast Track for New Vaccine During COVID-19 Pandemic
-Global Efforts Towards Coronavirus Vaccines：Can We Beat It?
-Technical Exploration of the Blue Ocean: Algal Polysaccharides
-NASH: Seizing Opportunities in the Untapped Market
-The Second ADC Approved for Marketing in China
-Chiatai Tianqing's High-difficulty Generic Drug "Fulvestrant Injection" Approved in the US: Sales of the Original Drug was $1.028 Billion in 2018
-Top 50 Drugs by Sales to Sample Hospitals in China in 2019
-A Comparison of the Biosimilar Accessibility of China, the EU, and the U.S.: China’s Biosimilars Commercialized at an Impressive Speed
- Old Drugs for New Indications
About Pharma Sources Insight
Insight is a unique source of updated coverages on current events and deep
insights into hot areas of the pharma industry, from China to the world. It
follows up new developments with the leading drug-manufacturers in China which
further affect the world.
PharmaSources.com to get access to the news of the Chinese pharmaceutical
enterprises and to witness industrial changes through the exclusive
perspectives of our expert writers into crucial aspects of the pharmaceutical
field, all under PharmaSources.com and CPhI China.
Click on the link or Scan the QR code to read the Pharma Sources Insight (June 2020):